ABSTRACT
Resumen El modelo de la psicopatología como red de síntomas propone centrarse en las interacciones dinámicas y causales entre los síntomas constitutivos del problema clínico. La idea principal es que la activación de un síntoma clínico lleva a la activación de otro síntoma vecino. Las conexiones entre ellos pueden ser biológicas, psicológicas o sociales. Los trastornos mentales son concebidos como estados estables alternativos de redes de síntomas fuertemente conectados. Esto permite un modelo explicativo común para todos los trastornos mentales, un modelo integral de psicopatología. A pesar del éxito de este nuevo camino metodológico, la mayoría de la información relevante se encuentra publicada en inglés. En este artículo, se presenta, en idioma español, la teoría de la psicopatología como red de síntomas y su modelo, su relevancia para la investigación, docencia y práctica clínica de la psicología y la psiquiatría, a los fines de incrementar su difusión y diseminación.
Abstract Over the past years, psychopathology has frequently been represented as a complex system, where psychiatric symptoms are causally interconnected in a network architecture. The network theory of psychopathology has led to more than 300 novel publications, academic courses, methodology for estimating novel models, and freely available software. However, despite the success of this novel research avenue, all relevant information has mostly been published in English. This paper translates the network theory of psychopathology and its model, together with its relevance for research and clinical practice of psychology and psychiatry, to the Spanish language. To serve the dissemination of this theory, this paper serves as an introductory paper for Spanish scholars, for example, as a starting point to learn more about the approach or for academic courses. The main idea of the network theory of psychopathology is that the activation of one clinical symptom in the network leads to the activation of a neighboring symptom. If symptoms are strongly connected with each other, for example, excessive worry and insomnia, they are more likely to be in the same state, meaning that if a person faces a stressful life event such as losing one's job, the activation of the symptom excessive worry will increase the probability they will also suffer from insomnia. In this way, a whole symptom activation pattern develops from which mental disorders emerge. Mental disorders are conceived as stable states of strongly connected symptom networks, allowing for a common explanatory model for multiple mental disorders, thereby providing a comprehensive model of psychopathology. Traditional representations of mental disorders conceptualize symptoms as merely passive indicators of latent, underlying mental disorders which act as common causes for patients' symptomatology. The network theory of psychopathology flips the explanatory and statistical model: instead of focusing on one underlying cause or underlying causes, it proposes to study the direct interactions between these symptoms. This imposes two important implications for the conceptualization of mental disorders. First, symptoms are no longer statistically exchangeable since every symptom can have a different role in the onset and development of psychopathology. Some symptoms can be more important than others in keeping the whole system "stuck" in a disordered state. Second, comorbidity is conceptualized as clustering symptoms which are connected to each other via certain "bridge symptoms". Bridge symptoms are symptoms which are attributed to two (or more) mental disorders, such as Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). If a person suffers from symptoms of MDD, such as loss of motivation and depressed mood, this can lead to the activation of bridge symptoms such as fatigue and concentration problems, which by themselves lead to the activation of GAD symptoms such as irritability and excessive worry.
ABSTRACT
Abstract Introduction: Initial treatment of the HIV is based on the use of three drugs, two of which are nucleoside analog reverse-transcriptase inhibitors. There are three combinations of these drugs which have been approved by different guidelines, each with divergent results in terms of efficacy and safety. Objective: To compare the efficacy and safety of these three combinations. Methods: Systematic review and network meta-analysis of randomized clinical trials comparing fixed doses of Tenofovir Disoproxil Fumarate / Emtricitabine (TDF/FTC), Abacavir / Lamivudine (ABC/3TC) and Zidovudine / Lamivudine (ZDV/3TC). Results: Seven clinical trials met the eligibility criteria. The results suggested higher efficacy with TDF/FTC vs. ABC/3TC at 96 weeks and vs. ZDV/3TC at 48 weeks. However, there is clinical and statistical heterogeneity. Subgroup analysis were performed by third drug and by level of viral load prior to treatment, and found no differences in virological control. Network meta-analysis could only be carried out with TDF/FTC vs. ZDV/3TC, and the proportion of patients with virological response, with no differences at 48 weeks nor at 96 weeks. Direct comparisons showed an increased risk of bone marrow suppression of ZDV/3TC vs. TDF/FTC and of ABC/3TC hypersensitivity reactions vs. ZDV/3TC Conclusions: The results did not show differences in effectiveness among the interventions. However, due to the heterogeneity of the third drug and the follow-up time between the included studies, this result is not definitive. The results raise the need for further studies to help improve treatment recommendations in patients infected with HIV.
Resumen Introducción: El tratamiento inicial de la infección por VIH se basa en el uso de tres medicamentos, dos de ellos inhibidores de transcriptasa reversa análogos de nucleósido. Existen tres combinaciones de estos medicamentos aprobadas por diferentes guías, con resultados divergentes en cuanto a eficacia y seguridad. Objetivo: Comparar la eficacia y seguridad de las 3 combinaciones Métodos: Revisión sistemática y metanálisis en red de ensayos clínicos con asignación aleatoria comparando dosis fijas de Tenofovir Disoproxil Fumarato/Emtricitabina (TDF/FTC), Abacavir/Lamivudina (ABC/3TC) y Zidovudina/Lamivudina (ZDV/3TC). Resultados: Siete ensayos clínicos cumplieron los criterios de elegibilidad. Los resultados sugirieron mayor eficacia con TDF/FTC vs ABC/3TC a 96 semanas y vs. ZDV/3TC a 48 semanas. Sin embargo, existe heterogeneidad clínica y estadística. Se realizó análisis de subgrupos por tercer medicamento y por nivel de carga viral previa al tratamiento, sin encontrar diferencias en control virológico. Se pudo realizar metanálisis en red con TDF/FTC vs ZDV/3TC y proporción de pacientes con respuesta virológica, sin diferencias a las 48 semanas ni 96 semanas. Las comparaciones directas evidenciaron mayor riesgo de supresión de médula ósea de ZDV/3TC vs TDF/FTC y de reacciones de hipersensibilidad de ABC/3TC vs ZDV/3TC. Conclusión: Los resultados no demostraron diferencias en efectividad entre las intervenciones; sin embargo, debido a heterogeneidad en cuanto al tercer medicamento y el tiempo de seguimiento entre los estudios incluidos, dicho resultado no es definitivo. Los resultados plantean la necesidad de realizar nuevos estudios que ayuden a mejorar las recomendaciones de tratamiento en los pacientes infectados por el VIH.